ARCH Venture Fund IX Overage, L.P.
Entity reporting insider trades (Form 4): 10% owner CIK 1666307Its filings on EDGARAll insiders
Measures activity, not value. Not investment advice.
Since 16 Oct 2019, sold $40K in 1 sale and bought $33.2M in 3 open-market purchases across 4 companies.
Companies
Role on the latest Form 4 for each; open-market trades counted| Company | Role | Trades from | to | Purchases | Sales |
|---|---|---|---|---|---|
| Vir Biotechnology VIR | 10% owner | 16 Oct 2019 | 16 Oct 2019 | 1$20.0M | – |
| Sana Biotechnology SANA | 10% owner | 8 Feb 2024 | 8 Feb 2024 | 1$10.0M | – |
| Boundless Bio BOLD | 10% owner | 2 Apr 2024 | 1 Jul 2026 | 1$3.2M | 1$40K |
| Lyell Immunopharma LYEL | 10% owner | 6 Mar 2026 | 4 Nov 2026 | – | – |
What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.
Median return minus the sector fund, in percentage points; "too few trades" under 5| Open-market trades | After 3 months | After 6 months | After 12 months |
|---|---|---|---|
| After purchases | too few trades3 trades | too few trades3 trades | too few trades3 trades |
| After sales | too few trades1 trade | no trade old enough | no trade old enough |
For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.
By year
Counted open-market trades, by trade date| Year | Purchases | Bought | Sales | Sold | Net |
|---|---|---|---|---|---|
| 2026 | – | – | 1 | $40K | -$40K |
| 2024 | 2 | $13.2M | – | – | $13.2M |
| 2019 | 1 | $20.0M | – | – | $20.0M |
Every trade
6, newest first; open-market purchases and sales only| Trade date | Company | Side | Shares | Price | Value | Planned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. | Filing |
|---|---|---|---|---|---|---|---|
| 4 Nov 2026 | Lyell Immunopharma LYELfiled jointly with 4 others | Buythe same trade was reported by another filer; counted there | 0 | Not filed | Not filed | No | Form 4filed 5 Nov 2026 |
| 1 Jul 2026 | Boundless Bio BOLDfiled jointly with 7 others | Sellafter exercising options | 16,000 | $2.49 | $40K | No | Form 4filed 6 Jul 2026 |
| 6 Mar 2026 | Lyell Immunopharma LYELfiled jointly with 4 others | Buythe same trade was reported by another filer; counted there | 0 | Not filed | Not filed | No | Form 4filed 9 Mar 2026 |
| 2 Apr 2024 | Boundless Bio BOLDfiled jointly with 7 others | Buy | 200,000 | $16.00 | $3.2M | No | Form 4filed 4 Apr 2024 |
| 8 Feb 2024 | Sana Biotechnology SANAfiled jointly with 9 others | Buy | 1,818,181 | $5.50 | $10.0M | No | Form 4filed 12 Feb 2024 |
| 16 Oct 2019 | Vir Biotechnology VIRfiled jointly with 6 others | Buy | 1,000,000 | $20.00 | $20.0M | Not stated | Form 4filed 18 Oct 2019 |
From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.